Myriad Genetics, Inc. (MYGN)

Over the past six months, Myriad Genetics' stock has experienced a significant decline, with a 52.22% decrease as of December 23, 2025. Key events impacting the stock include Q3 CY2025 earnings, which met revenue expectations but faced market negativity due to challenges in average revenue per test and operational headwinds. Reduced coverage for GeneSight and the divestiture of the European EndoPredict business also impacted revenue. Analyst downgrades occurred in November 2025 due to flat Q3 earnings and limited near-term revenue growth. The company cited strong volume growth in the oncology segment, particularly for its MyRisk hereditary cancer test.

Myriad Genetics expects its gross margin to fluctuate quarterly due to product mix, pricing trends, and seasonality. Q1 margins are typically lower than Q4 gross margins and are expected to increase throughout the rest of the year, indicating a seasonal pattern in demand.

Myriad Genetics, Inc., founded in 1991 and headquartered in Salt Lake City, Utah, operates in the healthcare sector, focusing on molecular diagnostics, biotechnology, and precision medicine. The company develops and commercializes molecular diagnostic tests to guide treatment decisions in oncology, women's health, and mental health. Key products include MyRisk Hereditary Cancer, Prolaris, GeneSight, BRACAnalysis CDx, Prequel, EndoPredict, and Precise Oncology Solutions. Revenue is generated through reimbursements from commercial payers, government programs, and direct patient payments.

Myriad Genetics, Inc. is based in Salt Lake City, Utah, United States, where its headquarters remain. The company's operational footprint is primarily in the United States, following the divestiture of its European EndoPredict business.

In the past year, Myriad Genetics has emphasized its commitment to quality, innovation, and corporate responsibility, highlighting operational excellence and high employee satisfaction. However, the discontinuation of UnitedHealthcare coverage for GeneSight and the divestiture of its European EndoPredict business have posed challenges. Despite these headwinds, the company maintained a robust gross margin and is strategically pivoting towards precision oncology and AI-driven diagnostics to bolster its market position.

Myriad Genetics, Inc. is primarily controlled by institutional investors, with approximately 58.64% of the company's stock owned by them. Insiders own 4.47%, and Public Companies and Individual Investors own 36.89%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and iShares Core S&P Small-Cap ETF (IJR).